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Introduction
Prostate cancer (PCa) is the most frequent cancer diagnosed in men, accounting for 15% of all male cancer cases diagnosed. Regardless of this incidence, the associated death rate remains relatively low since $10% of men diagnosed with PCa will die of their disease. According to randomized studies on localized PCa management (PIVOT, PROTECT, SPCG-4), 20% of cancers will progress to metastatic state and death after more than 10 years of follow-up. These studies suggest that a majority of cancers diagnosed at a localized stage are exposed to overtreatment.
In clinical practice, prognosis is principally based on D'Amico classification [1] or CAPRA score [2] , combining histological criteria such as Gleason score [3] , prostate-specific antigen (PSA) levels, and TNM classification. However, these tools fail to accurately identify patients whose PCa will not progress from those whose tumour will relapse and progress, even after local curative therapy such as prostatectomy.
The democratization of genomic profiling has considerably help to characterize PCa molecular heterogeneity and find relevant biomarkers. More importantly, molecular prognosis tools developed by academic or commercial institutions have been proved to increase the accuracy of risk predictions, demonstrating the utility of using information at the molecular level to adapt patient care [4] . The most recent molecular classification of prostate adenocarcinoma published by The Cancer Genome Atlas (TCGA) identified several subtypes of tumours, characterized by specific driver mutations or transcript fusions [5] . Yet, this characterization leaves 30% of PCa unclassified and no significant associations with relapse or prognosis was established. Also, the lack of consensus among published molecular classifications and prognostic molecular signatures makes it difficult to use the molecular characteristics within clinical routine [6] . A further understanding into PCa molecular heterogeneity is therefore necessary to generate efficient tools and markers that could be used by every clinician.
Here we report a classification of PCa into three molecular subtypes with distinct genomic, transcriptomic, epigenomic, and clinical features. This classification was revealed after considering sample purity, and reproduced on TCGA data for validation. Using five independent cohorts, we show that one molecular subtype is strongly predictive of BCR-free survival, and provide a list of robust surrogate biomarkers.
Methods

Patients and samples included in Cartes d'Identité des Tumeurs
V R cohort
The Cartes d'Identité des Tumeurs V R (CIT) retrospective cohort study included 130 patients with localized PCa from CHU Poitiers, CHU Pointe-à-Pitre/Abymes, GH Pitié-Salpétrière, CHU Brest, CHU Lille and Tenon hospital. All patients provided written informed consent consistent with local Research Ethics Board guidelines. The study protocol (CeRePP-PROGENE) was approved by the CPP Ile-de-France IV Institutional Review Board (IRB00003835).
A total of 195 samples were included in the CIT cohort: 130 tumours and 65 normal adjacent samples. An expert urological pathologist centrally reviewed all tumour specimens. Biochemical relapse was reported when patient PSA levels rose above 0.2 ng/ml followed by another increase after radical prostatectomy.
Sample details are given in supplementary Table S1 , available at Annals of Oncology online.
Procedures
CIT samples were profiled on mRNA expression arrays (E-MTAB-6128), DNA methylation arrays (E-MTAB-6131), and SNP arrays (E-MTAB-6126, E-MTAB-6127). Profiling protocols are described in supplementary methods, available at Annals of Oncology online. TCGA data were downloaded from Broad GDAC Firehose (doi:10.7908/C11G0KM9).
Samples tumour purity was estimated using an in silico method from DNA methylation arrays (supplementary methods, available at Annals of Oncology online). Molecular subtypes of prostate adenocarcinoma tumours were identified by unsupervised classifications of mRNA and DNA methylation data using consensus clustering methods (supplementary methods, available at Annals of Oncology online). Subtypes were confirmed on TCGA data by using the same approach. We built an mRNA predictor of these subtypes and used a deconvolution method (supplementary methods, available at Annals of Oncology online) to label the samples in three additional public datasets, and measure subtypes association with prognosis.
Statistical analysis
Association between molecular subtypes and categorical variables were measured by Fisher's exact or v 2 tests. Associations with continuous variables were evaluated by Kruskal-Wallis tests or ANOVA.
Relapse-free survival analyses were carried out on patients from five independent cohorts considering biochemical recurrence (BCR) as the relapse event. We built multivariate Cox models integrating molecular subtyping and clinical risk factors, stratified on each cohort (separate baseline hazard functions were fit for each strata). We constructed Kaplan-Meier curves and used log-rank tests to compare patient groups. All statistical and bioinformatics analyses were carried out with R software environment (version 3.3.2).
Results
Combined analysis of mRNA expression and DNA methylation reveals 3 distinct PCa molecular subtypes
We analysed 130 primary prostate adenocarcinoma samples and 65 adjacent normal prostate samples referred henceforth as the CIT cohort. These samples were all profiled on DNA methylation and SNP arrays, and 101 of them were also profiled on mRNA arrays as described in supplementary Table S1 , available at Annals of Oncology online. In order to avoid biases from normal cells contamination and define 'pure' molecular subtypes of prostate tumours, we first restricted the analysis to 63 samples containing more than 50% of tumour cells as estimated through their DNA methylation profiles (Figure 1 ; supplementary Figure S1 , available at Annals of Oncology online). Consensus hierarchical clustering of mRNA expression and DNA methylation data were remarkably consistent (P < 10
À15
, Fisher) and were combined into three stable molecular subtypes S1, S2, and S3, almost perfectly matching mRNA clusters, and hereafter referred to as CIT subtypes.
We validated this classification system using the same approach on public data from TCGA Prostate Adenocarcinoma (PRAD) cohort. De novo unsupervised classification of mRNA and DNA methylation profiles was carried out on 253 TCGA samples with more than 50% of tumour cells. The resulting classes were similarly combined into three stable subtypes with consistent mRNA and DNA methylation patterns (P < 10
À50
, Fisher), almost perfectly matching mRNA clusters, and were strongly correlated with initial CIT subtypes (Pearson's correlation from 0.5 to 0.7; supplementary Figure S2 , available at Annals of Oncology online), thereby validating the reliability of CIT subtypes.
We compared this three-class CIT system with the classification results published by TCGA in 2015 [5] and observed a high consistency (P < 10 À38 , Fisher) with their original subtypes and consensus classes (supplementary Figure S2 , available at Annals of Oncology online). Nevertheless, original TCGA mRNA classes were significantly associated with tumour sample purity (P < 10 À14 , Fisher), which probably biased the class identification and may explain the differences with CIT subtypes.
Comprehensive molecular characterization of S1, S2, and S3 subtypes
We built a transcriptomic classifier (supplementary methods, available at Annals of Oncology online) to predict CIT subtypes labels in CIT and TCGA samples that were not included in the classification process described above. We then used pooled data from CIT and TCGA cohorts to further characterize CIT subtypes using clinical data, mRNA signatures, copy number and mutation data ( Figure 2 ).
The analysis of mRNA and copy number data revealed a strong association of CIT subtypes with ERG fusion status: S1 and S2 subtypes strongly over-expressed the transcriptomic fusion signature (Fusþ) as defined in Setlur et al. [7] (P < 10
À20
, t-test), and the typical losses of TMPRSS2 genomic locus were over-represented in both subtypes (P < 10 À43 , Fisher). In contrast, S3 tumours showed neither transcriptomic nor genomic marks of the fusion (FusÀ). Figure 1 . Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data (130 samples of localized prostate adenocarcinoma and 65 samples of adjacent normal samples) to build an integrative molecular classification of prostate cancer. DNA methylation arrays from tumour and normal samples were used to assess the percentage of tumour cells in each sample. Only tumour samples containing more than 50% of tumour cells were selected to perform unsupervised consensus, both on mRNA and DNA methylation data. The resulting classes of each molecular layer were combined into integrative molecular subtypes using a cluster of cluster approach. The exact same process was similarly applied on TCGA published data from 333 patients. In both cohorts the analysis revealed three molecular subtypes almost perfectly matching the mRNA level clusters. The three-class systems obtained in each cohort were highly similar (supplementary Figure S1 , available at Annals of Oncology online). Heatmaps displaying the most differentially expressed features at the mRNA expression and DNA methylation level illustrate the similarity between CIT and TCGA 3-subtype systems.
While sharing the Fusþ molecular pattern, S1 and S2 subtypes showed distinct clinical and genomic properties. Eighty-three percent of S1 samples fell into ISUP group 3 or higher and harboured numerous significant losses of genomic loci (supplementary Figure  S3 and Table S2 , available at Annals of Oncology online). This subgroup was specifically associated with frequent deletions of PTEN (67%, P < 10
À33
). Mutations in TP53 gene were frequently found in S1 tumours (22%) and significantly associated with this subtype (P < 10 À4 , Fisher). Unlike S1 tumours, S2 tumours were enriched in low Gleason scores (33% of ISUP group 1) and harboured few genomic alterations. However, RYBP locus (3p13) was more frequently lost in S2 (45%) relatively to S1 tumours (27%) (P ¼ 0.002, Fisher), and TMPRSS2 mutations were only found in S2 tumours (5%). Consistent with the differences in their genomic profiles, S1 tumours transcriptomic profile showed a clear inactivation of p53 and PTEN pathways relatively to S2 tumours, together with higher proliferation signals and a diminished androgen response (P < 10
À13
, t-test). S3 tumours were all negative for the FusÀ signature. Our results confirmed the previously reported associations of FusÀ tumours with SPOP mutations (28%, P < 10 À18 , Fisher), FOXA1 mutations (15%, P < 10
À6
, Fisher) and frequent losses of chromosome arms 2q, 5q, and 6q [8] . CHD1 losses were found in 40% of S3 tumours (P < 10 À5 , Fisher). The loss of ZNF292 on 6q was observed in 65% of S3 tumours (P < 10 À13 , Fisher), ranking as the most frequently deleted locus in those tumours. As for arm Figure 2 . Clinical and molecular characterization of tumour subtypes using CIT and TCGA cohorts. A total of 510 samples from CIT and TCGA cohorts were assigned one of S1, S2, or S3 subtypes. (A) Clinical repartition of ISUP groups within subtypes. The pies show the proportion of ISUP groups within each subtype. (B) Molecular hallmarks of S1, S2, and S3 subtypes. mRNA expression data was available for 493 tumour samples. We searched for differentially enriched gene sets between subtypes as described in supplementary methods, available at Annals of Oncology online. Single sample GSEA was carried out to get an activity measure of each gene set for each sample, and resulting scores were centred and scaled for each cohort (CIT and TCGA). The mRNA signatures panel shows a selection of five gene sets which are differentially activated between the three subtypes. The activation levels in 53 adjacent normal samples (N) are displayed as a visual reference. The genomic alterations and exome data panels highlight genomic losses and mutation patterns of putative key driver genes whose alterations are significantly associated with the molecular classification. The copy number profiles of 504 tumour samples grouped by subtype was analysed by GISTIC2 to identify regions and genes that were significantly altered in each subtype (supplementary Table S2 , available at Annals of Oncology online). We used TCGA exome data from 371 tumour samples to identify significant subtype specific mutations. Mutation profiles are displayed for the top 10 genes that were detected as significantly mutated by MutSig algorithm and whose mutation rates were significantly different between subtypes. For each gene alteration (copy number loss or mutation) we used Fisher's exact tests to assess the association with subtypes. Stacked barplots on the right side shows the proportions of tumours in each subtype harbouring either a loss or a mutation of the genes.
2q, we identified a deletion peak encompassing SPOPL in 33% of S3 tumours (P < 10 À8 , Fisher). Finally, S3 tumours were also significantly associated with mutations of KDM6A (5.4%; P ¼ 0.004, Fisher) and BRAF (4.2%; P ¼ 0.017, Fisher), which are both related to epigenetic modifications in cancers.
S2 subtype is strongly associated with the absence of BCR after radical prostatectomy in four distinct cohorts Strikingly, among patients with S2 tumour, none had had a BCR in CIT cohort and only one had recurred in TCGA cohort. In order to assess the significance of this association, we predicted CIT subtypes in 3 additional cohorts with available mRNA and clinical data [9] [10] [11] , totalling 841 patients with primary prostate adenocarcinoma (Figure 3 ; supplementary Table S3 , available at Annals of Oncology online). Subtype clinical features and associations with ERG fusion in each cohort were consistent with the features observed in the CIT and TCGA discovery cohorts. A pooled analysis of the five cohorts revealed a strong association of CIT subtypes with BCR-free survival (P < 10
À10
, log-rank), particularly for S2 subtype relatively to other subtypes (P < 10
À7
, logrank). CIT subtypes were more predictive of BCR-free survival than any of the other unsupervised molecular subtypes identified by TCGA, Taylor et al., and Ross-Adams et al. (supplementary Figure S4 , available at Annals of Oncology online). Multivariate analysis including ISUP group, tumour stage, and PSA confirmed that S2 subtype was an independent prognostic factor of BCRfree survival (P ¼ 0.0019, likelihood; Figure 3B ). Taken alone, S2 versus non-S2 subtyping approach achieved a positive predictive value of 95.73% for the absence of BCR, which was the best score among significant predictive factors analysed.
S2 subtyping is a promising predictive tool for suspected indolent PCa
We compared S2 subtype predictive power with other molecular approaches, including marker panels from Prolaris V R , OncotypeDX V R , and Decipher V R assays. These tools are used by clinicians to better identify patients with aggressive tumours from patients who are not likely to progress. We used published data [4, 12, 13] to assign Prolaris-, OncotypeDX-, and Decipherlike scores to the 841 samples and compare their predictive power with S2 subtyping. As expected, we observed that S2 subtype was significantly associated with lower scores in the three systems as compared with S1 and S3 subtypes (P < 10
À13
; supplementary Figure S5 , available at Annals of Oncology online). The scores were then discretized to define prognostic groups of low aggressive cases. Predictions based on Proveri Inc. prognostic biomarkers [14] , and the molecular signature used by Irshad et al. [15] to identify patients with a non-evolutive disease were added to the comparison (supplementary methods, available at Annals of Oncology online). We finally demonstrated that S2 subtyping carried out the best to identify PCa without BCR, with a smaller BCR-associated hazard ratio than any low risk group defined with the other approaches ( Figure 3C ).
S2 subtype can be accurately identified with a list of 37 biomarkers
We aimed to identify a set of surrogate biomarkers to accurately diagnose S2 tumours in clinical routine. ERG-positive tumours can be detected with either immunohistochemistry [16] or a simple urine-based test [17] , both methods achieving very high specificity. We therefore focused on providing clinicians with biomarkers to isolate S2 tumours from S1 tumours. Using the 5 cohorts and an iterative procedure to get a stable list of biomarkers (supplementary methods, available at Annals of Oncology online), we identified a robust set of 36 discriminant genes between S1 and S2 subtypes (supplementary Table S4 , available at Annals of Oncology online). We checked the discriminative power of this geneset (CIT36) by building simple linear classifiers and achieved 81% of specificity and 90% of sensitivity (supplementary methods, available at Annals of Oncology online). As expected, CIT36 predictions were strongly associated with BCR among ERG-positive tumours (P < 10
À5
, Figure 3D ). We searched for previously published evidence associating each of these genes with PCa prognosis and found PubMed publications of interest for 22 of them, thereby strengthening the relevance of this gene set as well as S2 subtype prognosis value. We therefore propose 37 biomarkers (ERG-positive marker þCIT36 signature) as a diagnostic tool for non-evolutive cases of PCa.
Discussion
This study proposes a comprehensive molecular classification of prostate adenocarcinoma integrating several molecular levels. Using an in silico method to discard low purity tumour samples, we could define three molecular subtypes of prostate tumours S1, S2, and S3, showing distinct features at the genomic, transcriptomic, and epigenetic levels. We have shown that our classification is not only consistent with the most recent TCGA classification [5] but also contains a strong prognostic power that was lacking in their study. Here, we successfully combined molecular classification and prognosis implications on a large number of tumours including a new multi-omics cohort and four distinct major PCa cohorts.
Genomic ERG fusion is the molecular alteration most frequently observed in PCa ($50% of tumours) and is associated with clearly different genomic and molecular characteristics as shown in previously published studies [18, 19] . The present classification respects the separation between FusÀ and Fusþ tumours and confirms reported association of FusÀ tumours with SPOP mutations and genomic losses of 5q21, 6q14, and 2q22 regions [8] . Notably, frequent losses of ZNF292 (6q14) and SPOPL(2q22) identify these genes as new candidate tumour suppressors (TS) in FusÀ tumours. ZNF292 has already been described as a TS gene in colorectal cancer [20] and SPOPL is an SPOP paralog sharing 85% sequence identity [21] , suggesting a possible TS role for SPOPL as well.
More importantly, this study identifies two distinct molecular subtypes within Fusþ tumours (S1 and S2), at the transcriptomic and genomic level. Apart from TMPRSS2-ERG fusion and region 3p13 losses, S2 tumours show considerably less genomic alterations than S1 tumours, suggesting that patients with these Figure 3 . Association of molecular subtypes with patient prognosis. (A) Meta-analysis of BCR-free survival. Five cohorts were used to study the association of CIT subtypes with prognosis. Clinical characteristics associated with CIT subtypes in each cohort are reported on the upper panel. ERG fusion status was assigned using transcriptomic signature from Setlur et al. [7] . Kaplan-Meier plots show the evolution of patients' BCR-free survival, stratified by molecular subtypes. We used data from 746 patients with available clinical follow-up data, and generated Kaplan-Meier curves to estimate BCR-free survival. We used log-rank tests to evaluate the significance of differences between patient survival distributions when comparing S1, S2, and S3 subtypes (left panel) or S2 relatively to S1 and S3 subtypes (right panel). (B) Multivariate recurrence-free survival analysis using Cox regression model. Regression analysis was carried out on 729 samples with complete annotations for the included factors, and stratified on cohorts. For each predictive factor, we reported the hazard ratio (HR) associated with BCR, as well as the corresponding confidence intervals and likelihood test P-values. We also reported Fisher's exact test P-values and positive predictive values (PPV) associated with each factor used to predict the absence of BCR. (C) Prognostic power of S2 subtyping relatively to other molecular approaches. We compared the prognostic significance of S2 subtype with low-risk groups defined by discretization of Prolaris-like, OncotypeDX-like, and Decipher-like scores, and to low-risk subtypes identified through the reproduction of Irshad et al. or Jia et al. (Proveri) computational methods (supplementary methods, available at Annals of Oncology online). Prolaris, OncotypeDx, and Decipher low-risk groups were defined by identifying cut-off values that best discriminated patients who had a BCR tumours may present an earlier stage of the disease. Indeed, TMPRSS2-ERG fusion is a starter event for tumorigenesis but not sufficient for full neoplastic transformation [22] . S2 may then correspond to preneoplastic lesions. This also suggests that the 3p13 loss may be an early event in prostate carcinogenesis.
Our work shows that these molecular differences between Fusþ subtypes S1 and S2 have significant implications at the clinical level, highlighting the importance of using molecular tests in clinical diagnostic routine to adapt patients' care. Molecular subtyping may be questioned to deal with PCa intra-tumoural heterogeneity. But although this heterogeneity was confirmed by our deconvolution approach (supplementary Figure S6 , available at Annals of Oncology online), our results suggest that patient prognosis still depends on the major subtype.
Overtreatment of patients with prostate tumours is unfortunately medically acknowledged. Medical studies agree that at least 20% of PCa are non-evolutive diseases and that patients could live with it without benefit of immediate radical treatment [23] . Our work suggests that patients with S2 tumours (here, 20% of patients) may correspond to those putative indolent cases who could reasonably be handled with active surveillance rather than undergoing radical surgery. We showed that S2 subtyping was a valuable tool to identify patients with an indolent disease, and outperformed the prognostic power of previously published classifications and molecular biomarkers. Consequently, we propose a list of 37 surrogate biomarkers (CIT36 þ ERG fusion positive marker) for the development of a new molecular test. CIT36 gene set results from the analysis of five independent cohorts of prostate tumour samples whose mRNA expression was measured through five different technologies including RNA-seq and four microarray technologies. We therefore assume that this gene set is preserved from common overfitting issues that may partly account for the lack of successful clinical transfer of previous set of biomarkers. Moreover, we showed that many of our biomarkers have been reported to be associated with PCa prognosis, including 11 down-regulated genes in S2 that are found up-regulated in the bad prognosis subtype described in Tandefelt et al. [24] . This set of markers identified through five distinct cohorts therefore constitutes a robust basis for developing a routine molecular assay and identifying S2 tumours which are not likely to evolve to a higher stage of the disease.
